4D Molecular Therapeutics, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
4D Molecular Therapeutics, Inc. (FDMT) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 13.89 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-13
- 4D Molecular Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 13.48M shares, a 10.29% increase year-over-year.
- 4D Molecular Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 12.22M shares, a 39.78% increase year-over-year.
- 4D Molecular Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 8.74M shares, a 24.83% increase year-over-year.
- 4D Molecular Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 7.00M shares, a 42.30% increase year-over-year.
- 4D Molecular Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 10.55M shares, a 0.23% increase from fiscal 2024.
- 4D Molecular Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 10.53M shares, a 20.24% increase from fiscal 2023.
- 4D Molecular Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 8.76M shares, a 40.63% increase from fiscal 2022.
- 4D Molecular Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 6.23M shares, a 58.22% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 13.89M shares 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | 13.48M shares 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 10.55M shares 10-K · filed 2026-03-18 | |||
| 2025-09-30 | 10.79M shares 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | 11.75M shares 10-Q · filed 2026-08-13 | |||
| 2025-03-31 | 12.22M shares 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | 10.53M shares 10-K · filed 2026-03-18 | |||
| 2024-09-30 | 9.45M shares 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | 8.75M shares 10-Q · filed 2025-08-11 | |||
| 2024-03-31 | 8.74M shares 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | 8.76M shares 10-K · filed 2025-02-28 | |||
| 2023-09-30 | 6.34M shares 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | 6.75M shares 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | 7.00M shares 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | 6.23M shares 10-K · filed 2024-02-29 | |||
| 2022-09-30 | 6.09M shares 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | 5.07M shares 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | 4.92M shares 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | 3.93M shares 10-K · filed 2023-03-15 | |||
| 2021-09-30 | 4.28M shares 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | 4.45M shares 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | 4.06M shares 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | 3.29M shares 10-K · filed 2022-03-28 | |||
| 2020-09-30 | 14.57M shares 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | 14.04M shares 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | 9.98M shares 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | 9.92M shares 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |